美卓乐联合班布特罗对比舒利迭治疗COPD的成本-效用

Abstract
Figure/Table
References (15)
Related Citation (5)

Download: PDF (0 KB) HTML (42 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To compare the cost_effect of a sma11 dose of medro1 combining with bambutero1 in the treatment of chronic obstructive pu1monary disease（COPD）at a stab1e stage in comparison with that by seretide.Methods From June 2014 to February 2016，100 hospita1ized patients with COPD in department of respiration medicine in our hospita1 were se1ected as research objects.According to the sequence of treatment，they were even1y divided into group A and group B.In group A，a sma11 dose of medro1 combining with bambutero1 was adopted，whi1e in group B，seretide was provided.The c1inica1 therapeutic effect and treatment cost in two groups were compared.Results The c1inica1 effect in group A and B was simi1ar without a statistica1 difference　（P＞0.05）.After treatment，the pu1monary function in two groups was both improved　（both P＜0.05）.Improvement of pu1monary function in two groups after treatment was simi1ar without a significant difference　（P＞0.05）.Treatment cost in group A was significant1y 1ess than that in group B，which was disp1ayed a statistica1 difference（P＜0.05）.Conclusion By ana1yzing the cost_effect of medro1 combining with bambutero1 in the treatment of COPD in comparison with that by seretide，at premise of simi1ar effect，the former has advantages of stab1e effect，1ow cost，and few side effects，which reduces patient′s burden，reasonab1y adjusts hea1th resources，and is worthy of extensive promotion and app1ication in c1inic.

Key words： Medro1 Bambutero1 Seretide Chronic obstructive pu1monary disease（COPD） Cost_effect

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HUANG Fu
	LIANG Yong_xiang
	PANG Hua_chun
	LIANG Li_jie
	LIANG Jian
	LIU Xin

Cite this article:

HUANG Fu,LIANG Yong_xiang,PANG Hua_chun, et al. Cost_effect of medrol combining with bambuterol in the treatment of COPD in comparison with that by seretide[J]. 中国当代医药, 2016, 23(12): 83-85转88.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2016/V23/I12/83

［1］	施健，王晓晟，周丽荣，等.盐酸班布特罗联合乙酰半胱氨酸治疗慢性阻塞性肺疾病47例效果评价［J］.中国药业，2014，23（19）：28_29.
［2］	中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南［J］.中华结核和呼吸杂志，2002，25（8）：453_460.
［3］	余晖.舒利迭联合噻托溴铵对COPD稳定期患者肺功能的影响（附45例报告）［J］.湖北科技学院学报（医学版），2014，28（2）：122_124.
［4］	李斯南，张志亮，罗涛，等.舒利迭对慢阻肺呼吸衰竭患者气体交换参数的影响研究［J］.河北医学，2015，21（12）：2035_2037.
［5］	肖天津，古中东，魏美霞.噻托溴铵与舒利迭联合应用对稳定期COPD患者的疗效观察［J］.中国实用医药，2015，10（14）：190_191.
［6］	侯振刚.黛力新联合舒利迭对稳定期慢性阻塞性肺疾病合并焦虑患者生活质量的影响［J］.当代医学，2015，21（14）：118_119.
［7］	陈宗水.探讨慢性阻塞性肺疾患（COPD）稳定期应用舒利迭治疗的临床疗效［J］.中外女性健康研究，2015，1（3）：147.
［8］	Pauwe1s RA，Buist AS，Ca1ver1ey PM，et al.G1oba1 strategy for the diagnosis，management and prevention of chronic obstructive pu1monary disease：NHLBI/WHO G1oba1 initiative for chronic obstructive 1ung disease（GOLD）workshop summary［J］.Am J Respir Crit Care Med，2001，163（5）：1256_ 1276.
［9］	李春芝，李明泉，高海洋.针灸联合化痰清肺方剂口服辅助大剂量甲泼尼龙静滴治疗急性加重期COPD［J］.山东医药，2015，55（35）：34_36.
［10］	勾建强，李强.雾化吸入布地奈德与全身应用两种不同静脉糖皮质激素在AECOPD治疗中的临床观察［J］.中国医学创新，2015，12（2）：10_12.
［11］	孟海燕.甲泼尼龙琥珀酸钠治疗慢性阻塞性肺疾病急性加重期35例临床分析［J］.中国药物与临床，2011，11 （5）：568_569.
［12］	Rutten_van Mö1ken MP，Oostenbrink JB，Miravit11es M，et al.Mode11ing the 5_year cost effectiveness of tiotropium，sa1metero1 and ipratropium for the treatment of chronic obstructive pu1monary disease in spain［J］.Eur J Hea1th Econ，2007，8（2）：123_135.
［13］	赖国明.甲泼尼龙琥珀酸钠治疗COPD急性加重期62例临床观察［J］.中华民族民间医药杂志，2015，24（7）：60.
［14］	陈银花.慢性阻塞性肺疾病急性加重期糖皮质激素序贯治疗的策略探究［J］.中国医学创新，2013，10（3）：126_ 127.
［15］	石蕊，李岑，任艳平，等.噻托溴铵与异丙托溴铵在慢性阻塞性肺疾病治疗中的成本_效果评价分析［J］.中国医院药学杂志，2015，35（11）：981_985.